Announcement on Voluntary Disclosure of Subsidiary’s YKYY032 Injection Obtaining Clinical Trial Approval from the National Medical Products Administration and FDA

Announcement on Voluntary Disclosure of Subsidiary’s YKYY032 Injection Obtaining Clinical Trial Approval from the National Medical Products Administration and FDA

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference: View Attachment